- Home
- FUTU vs RPRX Comparison
FUTU vs RPRX Comparison
Compare FUTU & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | RPRX |
|---|---|---|
| Founded | 2011 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5B | 19.5B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FUTU | RPRX |
|---|---|---|
| Price | $154.35 | $49.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $217.75 | $51.40 |
| AVG Volume (30 Days) | 1.0M | ★ 2.5M |
| Earning Date | 05-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.39% | 1.90% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $27.96 | $38.63 |
| Revenue Next Year | $11.89 | $4.73 |
| P/E Ratio | ★ $17.05 | $28.12 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $97.00 | $31.97 |
| 52 Week High | $202.53 | $50.47 |
Technical Indicators
Market Signals| Indicator | FUTU | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 58.41 |
| Support Level | $152.48 | $35.34 |
| Resistance Level | $155.54 | $50.08 |
| Average True Range (ATR) | 4.52 | 0.85 |
| MACD | -1.03 | -0.06 |
| Stochastic Oscillator | 21.37 | 58.46 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.